Direct contribution of vascular mineralocorticoid receptors to blood pressure regulation

Clinical and Experimental Pharmacology and Physiology

Volumn 40, Issue 12, 2013, Pages 902-909

  Barrett, Kathleen V ^a,b   Mccurley, Amy T ^a   Jaffe, Iris Z ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aldosterone; Blood pressure; Mineralocorticoid receptor; Nitric oxide; Reactive oxygen species; Vasoreactivity

Indexed keywords

ALDOSTERONE; CYCLIC GMP; DOXYCYCLINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROCHLOROTHIAZIDE; MINERALOCORTICOID RECEPTOR; NITRIC OXIDE; NORADRENALIN; REACTIVE OXYGEN METABOLITE; RHO KINASE; SPIRONOLACTONE;

ADRENERGIC SYSTEM; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; DIASTOLIC BLOOD PRESSURE; ENZYME ACTIVITY; ESSENTIAL HYPERTENSION; GENETIC TRANSCRIPTION; HEART RATE; HEART WEIGHT; HUMAN; HYPERTENSION; NONHUMAN; NORADRENALIN RELEASE; OXIDATIVE STRESS; PATHOGENESIS; PORTAL HYPERTENSION; PROTEIN DEPHOSPHORYLATION; PULMONARY HYPERTENSION; RESISTANCE BLOOD VESSEL; REVIEW; SMOOTH MUSCLE FIBER; SODIUM TRANSPORT; SYSTOLIC BLOOD PRESSURE; VASOCONSTRICTION; VASODILATATION;

ALDOSTERONE; BLOOD PRESSURE; MINERALOCORTICOID RECEPTOR; NITRIC OXIDE; REACTIVE OXYGEN SPECIES; VASOREACTIVITY;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RECEPTORS, MINERALOCORTICOID; VASODILATION;

EID: 84888075028     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12125     Document Type: Review

References (61)

1. Funder JW, Mihailidou AS. Aldosterone and mineralocorticoid receptors: Clinical studies and basic biology. Mol. Cell. Endocrinol. 2009; 301: 2-6.
2. Mosso L, Carvajal C, Gonzalez A et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161-5.
3. Calhoun DA, Jones D, Textor S et al. Resistant hypertension: Diagnosis, evaluation, and treatment: A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117: e510-26.
4. Levy DG, Rocha R, Funder JW. Distinguishing the antihypertensive and electrolyte effects of eplerenone. J. Clin. Endocrinol. Metab. 2004; 89: 2736-40.
5. + metabolism. Proc. Natl Acad. Sci. USA 1998; 95: 9424-9.
6. + metabolism. Kidney Int. 2000; 57: 1295-8.
7. Ronzaud C, Loffing J, Bleich M et al. Impairment of sodium balance in mice deficient in renal principal cell mineralocorticoid receptor. J. Am. Soc. Nephrol. 2007; 18: 1679-87.
8. Ronzaud C, Loffing J, Gretz N, Schutz G, Berger S. Inducible renal principal cell-specific mineralocorticoid receptor gene inactivation in mice. Am. J. Physiol. Renal Physiol. 2011; 300: F756-60.
9. Lombes M, Farman N, Bonvalet JP, Zennaro MC. Identification and role of aldosterone receptors in the cardiovascular system. Ann. Endocrinol. 2000; 61: 41-6.
10. Mendelsohn ME. In hypertension, the kidney is not always the heart of the matter. J. Clin. Invest. 2005; 115: 840-4.
11. Hofmann F. The biology of cyclic GMP-dependent protein kinases. J. Biol. Chem. 2005; 280: 1-4.
12. Forstermann U. Oxidative stress in vascular disease: Causes, defense mechanisms and potential therapies. Nat. Clin. Pract. Cardiovasc. Med. 2008; 5: 338-49.
13. Schulz E, Gori T, Munzel T. Oxidative stress and endothelial dysfunction in hypertension. Hypertens. Res. 2011; 34: 665-73.
14. Maron BA, Zhang YY, White K et al. Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension. Circulation 2012; 126: 963-74.
15. Maron BA, Zhang YY, Handy DE et al. Aldosterone increases oxidant stress to impair guanylyl cyclase activity by cysteinyl thiol oxidation in vascular smooth muscle cells. J. Biol. Chem. 2009; 284: 7665-72.
16. Nagata D, Takahashi M, Sawai K et al. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension 2006; 48: 165-71.
17. McCurley A, Jaffe IZ. Mineralocorticoid receptors in vascular function and disease. Mol. Cell. Endocrinol. 2012; 350: 256-65.
18. Mutoh A, Isshiki M, Fujita T. Aldosterone enhances ligand-stimulated nitric oxide production in endothelial cells. Hypertens. Res. 2008; 31: 1811-20.
19. Leopold JA, Dam A, Maron BA et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat. Med. 2007; 13: 189-97.
20. Iwashima F, Yoshimoto T, Minami I, Sakurada M, Hirono Y, Hirata Y. Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. Endocrinology 2008; 149: 1009-14.
21. Caprio M, Newfell BG, la Sala A et al. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ. Res. 2008; 102: 1359-67.
22. Callera GE, Montezano AC, Yogi A et al. c-Src-dependent nongenomic signaling responses to aldosterone are increased in vascular myocytes from spontaneously hypertensive rats. Hypertension 2005; 46: 1032-8.
23. Callera GE, Touyz RM, Tostes RC et al. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 2005; 45: 773-9.
24. McCurley A, Pires PW, Bender SB et al. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat. Med. 2012; 18: 1429-33.
25. Preston IR, Sagliani KD, Warburton RR, Hill NS, Fanburg BL, Jaffe IZ. Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 2013; 304: 678-88.
26. Kirsch T, Beese M, Wyss K et al. Aldosterone modulates endothelial permeability and endothelial nitric oxide synthase activity by rearrangement of the actin cytoskeleton. Hypertension 2012; 61: 501-8.
27. Luo W, Meng Y, Ji HL et al. Spironolactone lowers portal hypertension by inhibiting liver fibrosis, ROCK-2 activity and activating NO/PKG pathway in the bile-duct-ligated rat. PLoS One 2012; 7: e34230.
28. Garcia-Cardena G, Fan R, Stern DF, Liu J, Sessa WC. Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1. J. Biol. Chem. 1996; 271: 27 237-40.
29. Pojoga LH, Adamova Z, Kumar A et al. Sensitivity of NOS-dependent vascular relaxation pathway to mineralocorticoid receptor blockade in caveolin-1-deficient mice. Am. J. Physiol. Heart Circ. Physiol. 2010; 298: H1776-88.
30. Favre J, Gao J, Zhang AD et al. Coronary endothelial dysfunction after cardiomyocyte-specific mineralocorticoid receptor overexpression. Am. J. Physiol. Heart Circ. Physiol. 2011; 300: H2035-43.
31. Nishiyama A, Yao L, Nagai Y et al. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 2004; 43: 841-8.
32. Endemann DH, Touyz RM, Iglarz M, Savoia C, Schiffrin EL. Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 2004; 43: 1252-7.
33. Hirono Y, Yoshimoto T, Suzuki N et al. Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: The possible role of local renin-angiotensin system. Endocrinology 2007; 148: 1688-96.
34. Beswick RA, Dorrance AM, Leite R, Webb RC. NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension 2001; 38: 1107-11.
35. Macdonald JE, Kennedy N, Struthers AD. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 2004; 90: 765-70.
36. Renke M, Tylicki L, Knap N et al. High-dose angiotensin-converting enzyme inhibitor attenuates oxidative stress in patients with chronic kidney disease. Nephrol. Dial. Transplant. 2009; 24: 689-90.
37. Leopold JA. Rapid aldosterone signaling and vascular reactivity: Relax or don't do it. J. Cardiovasc. Pharmacol. 2009; 54: 465-7.
38. Heylen E, Huang A, Sun D, Kaley G. Nitric oxide-mediated dilation of arterioles to intraluminal administration of aldosterone. J. Cardiovasc. Pharmacol. 2009; 54: 535-42.
39. Schmidt BM, Oehmer S, Delles C et al. Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension 2003; 42: 156-60.
40. Uhrenholt TR, Schjerning J, Hansen PB et al. Rapid inhibition of vasoconstriction in renal afferent arterioles by aldosterone. Circ. Res. 2003; 93: 1258-66.
41. Liu SL, Schmuck S, Chorazcyzewski JZ, Gros R, Feldman RD. Aldosterone regulates vascular reactivity: Short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 2003; 108: 2400-6.
42. Nguyen Dinh Cat A, Griol-Charhbili V, Loufrani L et al. The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J. 2010; 24: 2454-63.
43. Farquharson CA, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: Evidence for an aldosterone-induced vasculopathy. Clin. Sci. 2002; 103: 425-31.
44. Schmidt BM, Montealegre A, Janson CP et al. Short term cardiovascular effects of aldosterone in healthy male volunteers. J. Clin. Endocrinol. Metab. 1999; 84: 3528-33.
45. Romagni P, Rossi F, Guerrini L, Quirini C, Santiemma V. Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis 2003; 166: 345-9.
46. Nietlispach F, Julius B, Schindler R et al. Influence of acute and chronic mineralocorticoid excess on endothelial function in healthy men. Hypertension 2007; 50: 82-8.
47. Wehling M, Spes CH, Win N et al. Rapid cardiovascular action of aldosterone in man. J. Clin. Endocrinol. Metab. 1998; 83: 3517-22.
48. Gunaruwan P, Schmitt M, Sharman J, Lee L, Struthers A, Frenneaux M. Effects of aldosterone on forearm vasculature in treated chronic heart failure. Am. J. Cardiol. 2005; 95: 412-4.
49. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000; 101: 594-7.
50. Nishizaka MK, Zaman MA, Green SA, Renfroe KY, Calhoun DA. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation 2004; 109: 2857-61.
51. Skott O, Uhrenholt TR, Schjerning J, Hansen PB, Rasmussen LE, Jensen BL. Rapid actions of aldosterone in vascular health and disease: Friend or foe? Pharmacol. Ther. 2006; 111: 495-507.
52. Wray DW, Supiano MA. Impact of aldosterone receptor blockade compared with thiazide therapy on sympathetic nervous system function in geriatric hypertension. Hypertension 2010; 55: 1217-23.
53. Esler M, Rumantir M, Kaye D et al. Sympathetic nerve biology in essential hypertension. Clin. Exp. Pharmacol. Physiol. 2001; 28: 986-9.
54. Ungvari Z, Kaley G, de Cabo R, Sonntag WE, Csiszar A. Mechanisms of vascular aging: New perspectives. J. Gerontol. A Biol. Sci. Med. Sci. 2010; 65: 1028-41.
55. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ. Res. 2005; 96: 643-50.
56. Mazak I, Fiebeler A, Muller DN et al. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation 2004; 109: 2792-800.
57. Rautureau Y, Paradis P, Schiffrin EL. Cross-talk between aldosterone and angiotensin signaling in smooth muscle cells. Steroids 2011; 76: 834-9.
58. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J. Biol. Chem. 1994; 269: 24 316-20.
59. Xiao F, Puddefoot JR, Barker S, Vinson GP. Mechanism for aldosterone potentiation of angiotensin II-stimulated rat arterial smooth muscle cell proliferation. Hypertension 2004; 44: 340-5.
60. Gradman AH. Role of angiotensin II type 1 receptor antagonists in the treatment of hypertension in patients aged > or = 65 years. Drugs Aging 2009; 26: 751-67.
61. Logan AG. Hypertension in aging patients. Expert Rev. Cardiovasc. Ther. 2011; 9: 113-20.